Abstract
Anemia is common in inflammatory bowel disease (IBD), with a prevalence ranging from 8.8% to 73.7%. This wide range reflects the definitions used and the populations studied. Although many patients are reported to be asymptomatic, systematic studies have shown anemia to have a significant impact on quality of life. Consequently treatment should be instituted early. The commonest cause of anemia in IBD is iron deficiency, predominantly related to gastrointestinal blood loss. Anemia of chronic disease often occurs concomitantly, due to cytokine-mediated impaired erythropoiesis and dysregulated iron metabolism. Oral iron is a simple and effective method for treating iron deficiency, but requires long courses of treatment. It is also theoretically implicated with worsening intestinal inflammation, via the production of toxic reactive oxygen species. Intravenous iron avoids these concerns, especially with the development of ferric carboxymaltose, which allow up to 1000mg to be given rapidly. In patients failing to respond to intravenous iron, the anemia of chronic disease is most likely to be causative. In this setting evidence suggests that additional erythropoietin therapy can be effective. Blood transfusions should be avoided as part of routine management and reserved for patients with substantial acute gastro-intestinal bleeding, where there is a risk of hemodynamic compromise. This article discusses the underlying physiology of anemia in IBD, and presents the current evidence supporting treatment options available.
Keywords: Inflammatory bowel disease, anemia, Crohn’s disease, ulcerative colitis, iron deficiency, anemia of chronic disease, hemoglobin
Current Drug Delivery
Title:What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Volume: 9 Issue: 4
Author(s): Alexandra J. Kent, Victoria J. Blackwell and Simon P.L. Travis
Affiliation:
Keywords: Inflammatory bowel disease, anemia, Crohn’s disease, ulcerative colitis, iron deficiency, anemia of chronic disease, hemoglobin
Abstract: Anemia is common in inflammatory bowel disease (IBD), with a prevalence ranging from 8.8% to 73.7%. This wide range reflects the definitions used and the populations studied. Although many patients are reported to be asymptomatic, systematic studies have shown anemia to have a significant impact on quality of life. Consequently treatment should be instituted early. The commonest cause of anemia in IBD is iron deficiency, predominantly related to gastrointestinal blood loss. Anemia of chronic disease often occurs concomitantly, due to cytokine-mediated impaired erythropoiesis and dysregulated iron metabolism. Oral iron is a simple and effective method for treating iron deficiency, but requires long courses of treatment. It is also theoretically implicated with worsening intestinal inflammation, via the production of toxic reactive oxygen species. Intravenous iron avoids these concerns, especially with the development of ferric carboxymaltose, which allow up to 1000mg to be given rapidly. In patients failing to respond to intravenous iron, the anemia of chronic disease is most likely to be causative. In this setting evidence suggests that additional erythropoietin therapy can be effective. Blood transfusions should be avoided as part of routine management and reserved for patients with substantial acute gastro-intestinal bleeding, where there is a risk of hemodynamic compromise. This article discusses the underlying physiology of anemia in IBD, and presents the current evidence supporting treatment options available.
Export Options
About this article
Cite this article as:
J. Kent Alexandra, J. Blackwell Victoria and P.L. Travis Simon, What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?, Current Drug Delivery 2012; 9 (4) . https://dx.doi.org/10.2174/156720112801323026
DOI https://dx.doi.org/10.2174/156720112801323026 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews In vivo Phenotyping Methods: Cytochrome P450 Probes with Emphasis on the Cocktail Approach
Current Pharmaceutical Design Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy The Urocortins: Mechanisms of Cardioprotection and Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects
Current Alzheimer Research The Development of Medications for Alcohol-Use Disorders Targeting the GABAB Receptor System
Recent Patents on CNS Drug Discovery (Discontinued) Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Anorexia Nervosa and the Use of Total Parenteral Nutrition Refeeding
Current Nutrition & Food Science Recent Advances of Calcium Phosphate Nanoparticles for Controlled Drug Delivery
Mini-Reviews in Medicinal Chemistry Structure-Function Relationships of Iodinated Contrast Media and Risk of Nephrotoxicity
Current Medicinal Chemistry Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review
Current Cardiology Reviews The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Reviews on Recent Clinical Trials Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Improvement of Nerve Fiber Density in Fibromyalgia Patients Treated with IVIg
Current Rheumatology Reviews